Beigene (NASDAQ:ONC – Get Free Report) is one of 1,069 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its peers? We will compare Beigene to related companies based on the strength of its valuation, profitability, risk, dividends, analyst recommendations, institutional ownership and earnings.
Analyst Ratings
This is a breakdown of recent ratings and price targets for Beigene and its peers, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Beigene | 0 | 0 | 3 | 0 | 3.00 |
| Beigene Competitors | 8341 | 22144 | 50251 | 1342 | 2.54 |
Beigene currently has a consensus target price of $310.00, indicating a potential upside of 23.55%. As a group, “Pharmaceutical preparations” companies have a potential upside of 217.60%. Given Beigene’s peers higher possible upside, analysts plainly believe Beigene has less favorable growth aspects than its peers.
Earnings & Valuation
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Beigene | $3.81 billion | -$881.71 million | -40.87 |
| Beigene Competitors | $9.93 billion | $136.87 million | -7.55 |
Beigene’s peers have higher revenue and earnings than Beigene. Beigene is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Risk and Volatility
Beigene has a beta of 0.65, meaning that its stock price is 35% less volatile than the S&P 500. Comparatively, Beigene’s peers have a beta of 3.65, meaning that their average stock price is 265% more volatile than the S&P 500.
Insider & Institutional Ownership
48.5% of Beigene shares are owned by institutional investors. Comparatively, 44.1% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 7.4% of Beigene shares are owned by company insiders. Comparatively, 13.7% of shares of all “Pharmaceutical preparations” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Profitability
This table compares Beigene and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Beigene | -25.94% | -25.12% | -14.95% |
| Beigene Competitors | -3,399.87% | -235.11% | -32.77% |
Summary
Beigene peers beat Beigene on 7 of the 13 factors compared.
About Beigene
BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.
Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.
